A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 428 participants.
Also called NCT06173570
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 428 participants
- Sponsor
- Registry
-
NCT06173570 -
2023-506197-12-00
-
- Other papers using this trial's data
- An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia: The PURSUIT Randomized Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Czechia, Denmark, Hungary, Japan, Slovakia, Spain
- Registry status
- Completed
Technical summary
Registry record NCT06173570. Randomized; quadruple masking; primary purpose treatment. Start 2024-01-19 (actual); primary completion 2024-09-30 (actual). Results posted on 2025-11-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia
- Acronym
- PURSUIT
- Condition
- Dyslipidemia
- Intervention (Drug)
- AZD0780
- Intervention (Drug)
- Placebo
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct06173570- Content hash
34a62c759bc22686565fad3bb0cfd942c1a290c5d08a2d68cc121e72b5e3a35f